RESEARCH MONOGRAPH · KDC-MN-139

BNN-27

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

53/100

A microneurotrophin with elegant design rationale and a frustratingly thin clinical pipeline

BNN-27 is a C17-spiro DHEA derivative designed by Achilleas Gravanis's group in Crete as a non-steroidal NGF mimetic. The design logic is clean: DHEA itself has neuroprotective effects but is steroidogenic, which limits its utility. By introducing a spiroketal at C17 you abolish the steroidogenic activity while preserving the neuroprotective profile, which the Gravanis group argued runs through low-affinity (p75NTR) and high-affinity (TrkA) neurotrophin receptor modulation. So you get a brain-permeable small molecule that mimics aspects of NGF signaling without being a peptide and without messing with the endocrine axis.

The preclinical literature is reasonably consistent across diabetic neuropathy models, retinal ganglion cell models, and various neurodegenerative paradigms. Effects on neurite outgrowth, neuronal survival, and inflammation markers in conditions where NGF signaling is compromised.

What we like: the design rationale is one of the cleanest examples of medicinal chemistry decoupling activities of interest from off-target steroidal effects we've seen. The microneurotrophin concept (small molecules that selectively modulate specific neurotrophin receptor signaling without the BBB and stability problems of NGF itself) is the right approach to a real problem. And BNN-27 in particular has good oral bioavailability and CNS penetration in rodent PK studies, which is more than you can say for most NGF mimetics.

What we dont like: clinical translation has been slow. There was a Phase 1 program but the published work past Phase 1 is thin, and the development through BionTech-adjacent Greek biotech entities hasnt produced major Phase 2 readouts as of when we've checked. So the human data set is essentially absent. We're working off animal pharmacology and design plausibility.

Mechanism: TrkA and p75NTR modulation in a manner thats not classical NGF agonism (BNN-27 doesnt directly mimic NGF binding) but appears to potentiate or sensitize NGF signaling. The exact molecular basis is still being worked out.

Sourcing: synthetic small molecule, characterizable by NMR and mass spec, accessible to standard synthesis. Vendor reliability is mixed because demand is low and the molecule isnt heavily commercialized.

Genuinely interesting design with thin human evidence. Worth watching, but not a priority research tool yet.

Evidence: 30
Mechanism: 60
Reliability: 50
Safety: 70
Sourcing: 55
Value: 50
Signal: 55
Staying power: 55

Plain-language summary Intrigue 70 / 100

BNN-27 is a synthetic neurosteroid derivative of DHEA developed at the BRFAA in Athens. It mimics nerve growth factor (NGF) without activating other DHEA pathways. Investigated for neurodegeneration. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Synthetic DHEA derivative / NGF mimetic

A synthetic DHEA derivative (17-spiroepoxy DHEA) developed at Bionature E.A. Ltd as a selective TrkA agonist mimicking NGF activity.

Abstract

BNN-27 (17-spiro-(2'-amino-1',3'-thiazolin-2-yl)-androst-5-en-3-beta-ol) is a synthetic DHEA derivative developed by Bionature E.A. Ltd (Greece) and Achilleas Gravanis's group for selective activation of TrkA, the high-affinity NGF receptor. The compound is a microneurotrophin: it mimics the NGF/TrkA pathway without binding to the p75 neurotrophin receptor (NTR). Animal studies show neuroprotective effects in models of diabetic neuropathy, retinal degeneration, and Alzheimer disease. The compound has not advanced to large clinical trials. Pharmacokinetics: oral bioavailability is good (steroid scaffold). Sold as research peptide/compound.

Mechanism of action

Selective TrkA receptor activator (NGF mimetic); DHEA-derived microneurotrophin.

Reported research dose ranges

Research-grade dosing not formally established in humans.

References

Pediaditakis I, et al. BNN27, a 17-spiroepoxy steroid derivative, interacts with and activates TrkA. Front Pharmacol 2016.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-139

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

BNN-27

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs